Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients
PEDIATRIC BLOOD & CANCER(2019)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined